| Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma (NCT00253630) | National Cancer Institute (NCI) | 2005-09-01 |
| HLA-B35 Alleles and AIDS (NCT00340223) | National Cancer Institute (NCI) | 2005-09-01 |
| Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma (NCT00132028) | National Cancer Institute (NCI) | 2005-09-01 |
| A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) (NCT00244881) | National Cancer Institute (NCI) | 2005-09-01 |
| Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer (NCT00100750) | National Cancer Institute (NCI) | 2005-09-01 |
| Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT00255658) | National Cancer Institute (NCI) | 2005-09-01 |
| Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma (NCT00245102) | National Cancer Institute (NCI) | 2005-09-01 |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00262847) | National Cancer Institute (NCI) | 2005-09-01 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma (NCT00121225) | National Cancer Institute (NCI) | 2005-09-01 |
| Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia (NCT00303823) | National Cancer Institute (NCI) | 2005-09-01 |
| Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer (NCT00103194) | National Cancer Institute (NCI) | 2005-09-01 |
| Radiation Therapy in Treating Patients With Cervical Cancer (NCT00278304) | National Cancer Institute (NCI) | 2005-09-01 |
| Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme (NCT00238303) | National Cancer Institute (NCI) | 2005-09-01 |
| Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer (NCT00096109) | National Cancer Institute (NCI) | 2005-09-01 |
| Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery (NCT00091078) | National Cancer Institute (NCI) | 2005-09-01 |
| Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer (NCT00179309) | National Cancer Institute (NCI) | 2005-09-01 |
| Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer (NCT00126581) | National Cancer Institute (NCI) | 2005-08-15 |
| Effect of High-Legume Diet on Colorectal Cancer Risk (NCT00339469) | National Cancer Institute (NCI) | 2005-08-03 |
| PRelationship Between Physical Activity and Cancer Ris (NCT00521651) | National Cancer Institute (NCI) | 2005-08-01 |
| Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome (NCT00342602) | National Cancer Institute (NCI) | 2005-08-01 |
| Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia (NCT00217412) | National Cancer Institute (NCI) | 2005-08-01 |
| Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma (NCT00243035) | National Cancer Institute (NCI) | 2005-08-01 |
| Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) (NCT00111384) | National Cancer Institute (NCI) | 2005-07-27 |
| Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer (NCT00238420) | National Cancer Institute (NCI) | 2005-07-26 |
| Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer (NCT00124917) | National Cancer Institute (NCI) | 2005-07-21 |
| Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia (NCT00117845) | National Cancer Institute (NCI) | 2005-07-11 |
| Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families (NCT00393224) | National Cancer Institute (NCI) | 2005-07-05 |
| Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT00103259) | National Cancer Institute (NCI) | 2005-07-01 |
| 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer (NCT00081276) | National Cancer Institute (NCI) | 2005-07-01 |
| Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer (NCT00182689) | National Cancer Institute (NCI) | 2005-07-01 |
| Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors (NCT00227513) | National Cancer Institute (NCI) | 2005-07-01 |
| Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (NCT00118183) | National Cancer Institute (NCI) | 2005-07-01 |
| Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer (NCT00126607) | National Cancer Institute (NCI) | 2005-07-01 |
| Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer (NCT00182702) | National Cancer Institute (NCI) | 2005-07-01 |
| Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma (NCT00217503) | National Cancer Institute (NCI) | 2005-07-01 |
| Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors (NCT00287937) | National Cancer Institute (NCI) | 2005-07-01 |
| Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors (NCT00138177) | National Cancer Institute (NCI) | 2005-07-01 |
| Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery (NCT00217542) | National Cancer Institute (NCI) | 2005-07-01 |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a (NCT00117013) | National Cancer Institute (NCI) | 2005-06-28 |
| Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer (NCT00118040) | National Cancer Institute (NCI) | 2005-06-24 |
| EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma (NCT00114738) | National Cancer Institute (NCI) | 2005-06-15 |
| Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers (NCT00342641) | National Cancer Institute (NCI) | 2005-06-08 |
| Vaccine and Antibody Treatment of Prostate Cancer (NCT00113984) | National Cancer Institute (NCI) | 2005-06-08 |
| Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer (NCT00121251) | National Cancer Institute (NCI) | 2005-06-03 |
| Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer (NCT00126568) | National Cancer Institute (NCI) | 2005-06-01 |
| Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer (NCT00126594) | National Cancer Institute (NCI) | 2005-06-01 |
| Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer (NCT00118144) | National Cancer Institute (NCI) | 2005-06-01 |
| Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) (NCT00217373) | National Cancer Institute (NCI) | 2005-06-01 |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer (NCT00132002) | National Cancer Institute (NCI) | 2005-06-01 |
| Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00131989) | National Cancer Institute (NCI) | 2005-06-01 |
| Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma (NCT00121199) | National Cancer Institute (NCI) | 2005-06-01 |
| Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors (NCT00110032) | National Cancer Institute (NCI) | 2005-06-01 |
| Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NCT00138203) | National Cancer Institute (NCI) | 2005-06-01 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (NCT00131911) | National Cancer Institute (NCI) | 2005-06-01 |
| Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery (NCT00119249) | National Cancer Institute (NCI) | 2005-06-01 |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00110019) | National Cancer Institute (NCI) | 2005-06-01 |
| Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT00084682) | National Cancer Institute (NCI) | 2005-06-01 |
| Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer (NCT00217399) | National Cancer Institute (NCI) | 2005-06-01 |
| Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer (NCT00134069) | National Cancer Institute (NCI) | 2005-06-01 |
| Genetic Susceptibility to Factor VIII Inhibitors (NCT00344435) | National Cancer Institute (NCI) | 2005-05-24 |
| Central Nervous System Disease in HIV-infected Children on HAART (NCT00110331) | National Cancer Institute (NCI) | 2005-05-03 |
| CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00109967) | National Cancer Institute (NCI) | 2005-05-01 |
| Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer (NCT00113373) | National Cancer Institute (NCI) | 2005-05-01 |
| Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen (NCT00118157) | National Cancer Institute (NCI) | 2005-05-01 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT00095979) | National Cancer Institute (NCI) | 2005-05-01 |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer (NCT00126503) | National Cancer Institute (NCI) | 2005-05-01 |
| 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors (NCT00119236) | National Cancer Institute (NCI) | 2005-05-01 |
| CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer (NCT00112840) | National Cancer Institute (NCI) | 2005-05-01 |
| Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders (NCT00114257) | National Cancer Institute (NCI) | 2005-05-01 |
| Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer (NCT00089609) | National Cancer Institute (NCI) | 2005-04-19 |
| Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research (NCT00340353) | National Cancer Institute (NCI) | 2005-04-07 |
| Enzastaurin to Treat Recurrent Brain Tumor (NCT00108056) | National Cancer Institute (NCI) | 2005-04-07 |
| Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia (NCT00101088) | National Cancer Institute (NCI) | 2005-04-01 |
| Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma (NCT00109005) | National Cancer Institute (NCI) | 2005-04-01 |
| Smokefree.Gov Website in Helping United States Federal Employees Quit Smoking (NCT00245076) | National Cancer Institute (NCI) | 2005-04-01 |
| Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer (NCT00342836) | National Cancer Institute (NCI) | 2005-04-01 |
| Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma (NCT00124605) | National Cancer Institute (NCI) | 2005-04-01 |
| Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) (NCT00077441) | National Cancer Institute (NCI) | 2005-04-01 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (NCT00085254) | National Cancer Institute (NCI) | 2005-04-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia (NCT00098488) | National Cancer Institute (NCI) | 2005-04-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT00103272) | National Cancer Institute (NCI) | 2005-04-01 |
| Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00110214) | National Cancer Institute (NCI) | 2005-04-01 |
| Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors (NCT00108069) | National Cancer Institute (NCI) | 2005-04-01 |
| SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel (NCT00096499) | National Cancer Institute (NCI) | 2005-04-01 |
| Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma (NCT00112736) | National Cancer Institute (NCI) | 2005-04-01 |
| Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract (NCT00112671) | National Cancer Institute (NCI) | 2005-04-01 |
| Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia (NCT00098371) | National Cancer Institute (NCI) | 2005-04-01 |
| Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT00126542) | National Cancer Institute (NCI) | 2005-04-01 |
| GW572016 to Treat Recurrent Malignant Brain Tumors (NCT00107003) | National Cancer Institute (NCI) | 2005-03-30 |
| Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis (NCT00340119) | National Cancer Institute (NCI) | 2005-03-21 |
| Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes (NCT00104962) | National Cancer Institute (NCI) | 2005-03-01 |
| Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer (NCT00126490) | National Cancer Institute (NCI) | 2005-03-01 |
| Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer (NCT00126555) | National Cancer Institute (NCI) | 2005-03-01 |
| 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT00121264) | National Cancer Institute (NCI) | 2005-03-01 |
| Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT00112476) | National Cancer Institute (NCI) | 2005-03-01 |
| Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00112853) | National Cancer Institute (NCI) | 2005-03-01 |
| Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer (NCT00109811) | National Cancer Institute (NCI) | 2005-03-01 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas (NCT00101270) | National Cancer Institute (NCI) | 2005-03-01 |
| Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer (NCT00114283) | National Cancer Institute (NCI) | 2005-03-01 |
| Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer (NCT00077376) | National Cancer Institute (NCI) | 2005-03-01 |